Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/111702
Title: | Chronic sleep disruption alters gut microbiota, induces systemic and adipose tissue inflammation and insulin resistance in mice. |
Author: | Poroyko, Valeriy A. Carreras, Alba Khalyfa, Abdelnaby Khalyfa, Ahamed A. Leone, Vanessa Peris, Eduard Almendros López, Isaac Gileles-Hillel, Alex Qiao, Zhuanhong Hubert, Nathaniel Farré Ventura, Ramon Chang, Eugene B. Gozal, David |
Keywords: | Microbiologia mèdica Microbiota Obesitat Trastorns del son Medical microbiology Microbiota Obesity Sleep disorders |
Issue Date: | 14-Oct-2016 |
Publisher: | Nature Publishing Group |
Abstract: | Chronic sleep fragmentation (SF) commonly occurs in human populations, and although it does not involve circadian shifts or sleep deprivation, it markedly alters feeding behaviors ultimately promoting obesity and insulin resistance. These symptoms are known to be related to the host gut microbiota. Mice were exposed to SF for 4 weeks and then allowed to recover for 2 weeks. Taxonomic profiles of fecal microbiota were obtained prospectively, and conventionalization experiments were performed in germ-free mice. Adipose tissue insulin sensitivity and inflammation, as well as circulating measures of inflammation, were assayed. Effect of fecal water on colonic epithelial permeability was also examined. Chronic SF-induced increased food intake and reversible gut microbiota changes characterized by the preferential growth of highly fermentative members of Lachnospiraceae and Ruminococcaceae and a decrease of Lactobacillaceae families. These lead to systemic and visceral white adipose tissue inflammation in addition to altered insulin sensitivity in mice, most likely via enhanced colonic epithelium barrier disruption. Conventionalization of germ-free mice with SF-derived microbiota confirmed these findings. Thus, SF-induced metabolic alterations may be mediated, in part, by concurrent changes in gut microbiota, thereby opening the way for gut microbiome-targeted therapeutics aimed at reducing the major end-organ morbidities of chronic SF. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/srep35405 |
It is part of: | Scientific Reports, 2016, vol. 6, p. 35405 |
URI: | http://hdl.handle.net/2445/111702 |
Related resource: | https://doi.org/10.1038/srep35405 |
ISSN: | 2045-2322 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
667961.pdf | 1.23 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License